Renalytix Plc (AIM:RENX)
London · Delayed Price · Currency is GBP · Price in GBX 2.500
+0.300 (13.64%)
Mar 26, 2026, 3:02 PM GMT
Renalytix Market Cap
Renalytix has a market cap or net worth of 10.27 million as of March 26, 2026. Its market cap has decreased by -64.56% in one year.
Market Cap
10.27M
Enterprise Value
9.97M
Revenue
2.45M
Ranking
n/a
PE Ratio
n/a
Stock Price
2.50
Market Cap Chart
Since November 6, 2018, Renalytix's market cap has decreased from 64.58M to 10.27M, a decrease of -84.10%. That is a compound annual growth rate of -22.04%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 25, 2026 | 9.61M | -62.71% |
| Dec 31, 2025 | 25.78M | -27.58% |
| Dec 31, 2024 | 35.60M | 129.87% |
| Dec 29, 2023 | 15.49M | -71.47% |
| Dec 30, 2022 | 54.30M | -87.89% |
| Dec 31, 2021 | 448.32M | 27.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Nov 6, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 213.14B |
| GSK plc | 77.49B |
| Haleon | 32.56B |
| Smith & Nephew | 10.09B |
| Fusion Antibodies | 14.38M |
| CelLBxHealth | 10.80M |
| Cizzle Biotechnology Holdings | 9.91M |
| Genflow Biosciences | 9.91M |